Bio-techne

TECHApproved

Bio-Techne Corporation is a publicly traded life sciences company that develops, manufactures, and sells biotechnology reagents, instruments, and services for the research and clinical diagnostic markets. With a portfolio spanning protein research tools, spatial biology solutions, and diagnostic assays, the company serves customers across pharmaceutical, biotechnology, and academic research sectors. Bio-Techne has grown through strategic acquisitions and organic development to become a key supplier of critical research tools.

Market Cap

$8.1B

Employees

2,500-3,000

Focus

Diagnostics

TECH · Stock Price

USD 51.4857.38 (-52.71%)

Historical price data

AI Company Overview

Technology Platform

Bio-Techne provides a comprehensive portfolio of life sciences research tools including protein research reagents, spatial biology solutions, flow cytometry instruments, genomics tools, and clinical diagnostics across multiple technology platforms.

FDA Approved Drugs

IBTROZINDAJun 11, 2025

AVZIVIBLADec 6, 2023

METHOCARBAMOLANDAJun 12, 2023

Opportunities

Bio-Techne is well-positioned to capitalize on growing markets in spatial biology, single-cell analysis, and cell & gene therapy tools.

Strategic acquisitions and international expansion provide additional growth avenues in the expanding life sciences tools market.

Risk Factors

Key risks include dependence on cyclical R&D spending by pharmaceutical customers, intense competition from larger well-funded players, and the need for continuous technology innovation and strategic acquisitions to maintain market position.

Competitive Landscape

Bio-Techne competes with large diversified life sciences companies like Thermo Fisher Scientific and Danaher, as well as specialized players in specific segments. The company differentiates through its strong brand portfolio, innovative spatial biology solutions, and comprehensive protein research tools offering.

Publications

Patents

FDA Approvals